Pharmaceutical intervention in the indiscriminate use of ivermectin: a comparative study
DOI:
https://doi.org/10.33448/rsd-v10i11.19787Keywords:
Ivermectin; Pharmaceutical; Covid-19.Abstract
Introduction: The whole world is still experiencing a health emergency caused by the pandemic of the new SARS-Cov-2 coronavirus, recently, ivermectin, previously shown to have broad-spectrum antiviral activity in vitro, has been shown to be an inhibitor of the SARS-CoV-2 virus , in this scenario, the article aims to analyze the pharmaceutical performance in drugstores, and compare the pattern of consumption of the drug Ivermectin in the period of the Covid-19 pandemic in the city of Redenção-PA. Methods: An exploratory, retrospective descriptive study was carried out, with the methodological documental procedure in the evaluation of sales records of 05 (five) drugstores in the city of Redenção-PA on the indiscriminate use of ivermectin during the pandemic. The study was carried out by reviewing the sales reports issued in 3 (three) months, namely: March/April/May 2019/2020/2021, respectively. Results and discussion: During the study, a jump in the consumption of ivermectin was observed in 2020, due to the intense search for curative or preventive measures by Covid-19. On the other hand, we recorded a drop in sales of this medication in 2021, due to vaccination in Brazil and the performance of studies that highlight that in none of them the in vivo action of the medication was proven. Final Considerations: It is up to the pharmacist, the last link between the medication and the patient, to guide and prevent the indiscriminate use of ivermectin, since there is enough data to abandon the use of these medications, due to overwhelming evidence that they do not help in the treatment.
References
Brasil. (2012). Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Uso racional de medicamentos, temas selecionados, 9. http://biblioteca.cofen.gov.br/uso-racional-de-medicamentos-temas-selecionados/.
Cabezas Yaru, V. P., Ormeño Mondaca, E. A., & Pablaza Vargas, L. D. C. (2000). Automedicación de analgésicos no narcóticos: consultório. Santo Tomás. http://bases.bireme.br/cgibin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=LILACS&lang=p&nextAction=lnk&exprSearc h=284702& indexSearch=ID.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. (2020). O medicamento aprovado pela FDA ivermectina inibe a replicação do SARS-CoV-2 in vitro. Antiviral research, 178, 104787. https://www.sciencedirect.com/science/article/pii/S0166354220302011.
Chaves, E. F. (2020). Considerações sobre os medicamentos com potencial efeito farmacológico para o vírus sars-hcov-2 do departamento de farmácia da associação de medicina intensiva brasileira – amib. https://www.amib.org.br/fileadmin/user_upload/amib/2020/abril/16/Consideracoes_so bre_os_medicamentos_com_potencial_efeito_farmacologico_para_o_virus_SARS- HCoV-2_pelo_Departamento_de_Farmacia_AMIB_.pdf.
Choudhary., R. & Sharma, AK (2020). Uso potencial de drogas hidroxicloroquina, ivermectina e azitromicina no combate ao COVID-19: tendências, escopo e relevância. Novos micróbios e novas infecções , 35 , 100684: https://pubmed.ncbi.nlm.nih.gov/32322397/.
CNN. 1 a cada 5 brasileiros vítimas da Covid-19 morreu em Março de 2021. 2021. https://www.cnnbrasil.com.br/saude/2021/04/01/1-a-cada-5- brasileiros-vitima-da-covid-19-morreu-em-marco-de-2021.
Junior, C. R. E., do Nascimento Antonio, M. V., Imperador, C. H. L., Chin, C. M., & Bosquesi, P. L. (2020). Remdesivir, nitazoxanida e ivermectina na COVID-19. Ulakes Journal of Medicine, 1, 74-80: http://revistas.unilago.edu.br/index.php/ulakes/article/view/259.
Galato, D., Alano, G. M., Trauthman, S. C., & Vieira, A. C. (2008). A dispensação de medicamentos: uma reflexão sobre o processo para prevenção, identificação e resolução de problemas relacionados à farmacoterapia. Revista Brasileira de Ciências Farmacêuticas, 44, 465-475. https://www.scielo.br/scielo.php?pid=S1516- 93322008000300017&script=sci_abstract&tlng=pt..
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506. https://www.thelancet.com/journals/lancet/article/PIIS0140-67362030183-5/fulltext.
Laing, R., Gillan, V., & Devaney, E. (2017). Ivermectina - droga velha, novos truques? Trends in parasitology, 33 (6), 463-472. https://pubmed.ncbi.nlm.nih.gov/28285851/.
MARTINS, M. A. (2020). Pharmacists in response to the COVID-19 pandemic in Brazil: where are we? Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 11(3), 517-517: Martins/publication/344328879_Editorial_O_farmaceutico_no_enfrentamento_da_C OVID- 19_no_Brasil_onde_estamos_Version_in_Portuguese/links/5f68950292851c14bc8be 1fb/Editorial-O-farmaceutico-no-enfrentamento-da-COVID-19-no-Brasil-onde- estamos-Version-in-Portuguese.pdf.
MCF, M. (2015). Atenção farmacêutica no uso racional de medicamentos. Sci Health, 6(1), 7-14. http://arquivos.cruzeirodosuledu cacional.edu.br/principal/new/revista_scienceinhealth.
Oliveira, F. C. A. (2020). Análise preliminar da dispensação de ivermectina, em tempos de COVID-19, em farmácia de manipulação. 15 f. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Departamento de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte, Natal. https://monografias.ufrn.br/jspui/handle/123456789/10819.
Opas. Recomendação sobre o uso de ivermectina no tratamento de COVID. https://iris.paho.org/bitstream/handle/10665.2/52462/OP ASIMSCDECOVID19200033_por.pdf?sequence=1&isAllowed=y.
PersonI, O. C., dos Santos PugaII, M. E., do AmaralIII, J. L. G., & AtallahIV, Á. N. (2021). Intervenção com ivermectina para COVID-19 (SARS-CoV-2): sinopse baseada em evidências. Revista diagnóstico e tratamento• volume 26• edição. http://associacaopaulistamedicina.org.br/assets/up loads/revista_rdt/2d8a7c864c3de3.
Rizzo, E. (2020). Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn-schmiedeberg's Archives of Pharmacology, 393, 1153-1156: https://pubmed.ncbi.nlm.nih.gov/32462282/.
Rodrigues, N. H., & da Silva, L. G. A. (2020). Gestão da pandemia coronavírus em um hospital: relato de experiência profissional/Management of the coronavirus pandemic in a hospital: professional experience report. Journal of Nursing and Health, 10(4): https://periodicos.ufpel.edu.br/ojs2/index.php/enfermagem/article/view/18530.
Silva, C. Y. A. B., Ponciano, A. K. B & Luz, D. C. R. P. (2020). Automedicação durante a pandemia de Covid-19. Revista e-ciência. 3(9). http://www.revistafjn.com.br/revista/index.php/eciencia/article/view/967.
Silva, J. N. B., Brito, M. E. S., Júnior, D. A. S & Silva, A. S. (2020). A ivermectina possui ação terapêutica na Covid-19? Anais do Congresso de Geriatria e Gerontologia UNIFACIG. 1(1). http://pensaracademico.facig.edu.br/index.php/congressogeriatria/article/view/2317#:.
Silva, A. D., Silva, A., & Mendes, P. (2020). Boletim BiblioCovid: notícias falsas (fake news) e COVID-19.
Vasconcellos-Silva, P. R., & Castiel, L. D. (2020). COVID-19, as fake news e o sono da razão comunicativa gerando monstros: a narrativa dos riscos e os riscos das narrativas. Cadernos de Saúde Pública, 36: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2020000703001.
Vidotti, C. C. F & Hoefler, R. (2006). Apoio a transformação do exercício profissional do farmacêutico na farmácia comunitária. Boletim Farmacoterapêutica. Brasília, 11(1), 1-5. https://www.cff.org.br/sistemas/geral/revista/pdf/14/farmacoterapeutica.pdf.
Vieira, F. S. (2010). Assistência farmacêutica no sistema público de saúde no Brasil. Revista Panamericana de Salud Pública, 27, 149-156. http://bvsms.saude.gov.br/bvs/is_digital/is_0210/pdfs/IS30%282%29034.pdf .
WHO. (2002). Promoting rational use of medicines: core components. Promoción del uso racional de medicamentos: componentes centrales. https://apps.who.int/iris/handle/10665/67438.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Elismar dos Santos Souza; Weslayny Pereira Martins; Yolanda de Jesus Morais
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
